A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
← catalyst calendarNCT03845166 · readout in 12 d
Sponsored by Exelixis (industry) · EXEL — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
325actual
Sites
86
Countries
Australia, Belgium, Czechia +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-03-20 | actual | When the study began enrolling |
| Primary completion | 2026-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2019-02-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Neoplasm Malignant
- Renal Cell Carcinoma
- Hormone Receptor Positive Breast Carcinoma
- Metastatic Castration-resistant Prostate Cancer
- Colorectal Cancer
Interventions
- Drug: XL092
- Drug: Atezolizumab — also filed as Tecentriq®
- Drug: Avelumab — also filed as Bavencio®
Primary outcomes
what the primary-completion date above is the date OFDose-Escalation Stage: MTD/recommended dose for XL092
measured Up to 24 months
Cohort-Expansion Stage: Objective Response Rate (ORR)
measured Up to 24 months
Cohort-Expansion Stage (except Cohort H): Progression-Free Survival (PFS)
measured Up to 24 months
Cohort-Expansion Stage (Cohort H only): Overall Survival (OS)
measured Up to 24 months
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed